Brief: Jhbp Cy Says China's Nmpa Accepted New Drug Application For Gb491 (Lerociclib) With Fluvestran
March 28 (Reuters) - Genor Biopharma Holdings Ltd
6998.HK :
* CHINA'S NMPA OFFICIALLY ACCEPTED NEW DRUG APPLICATION FOR
GB491
(LEROCICLIB) IN COMBINATION WITH FLUVESTRAN
Source text for Eikon: ID:nHKS7K2CVY
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: JHBP CY Says Chairman And CEO Ni Xin To Buy Shares Up To USD 1 Million From Aug 31, 2026
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA